Hair Loss on Mounjaro & Wegovy Ireland: Causes & Timeline

Noticing more hair in the shower drain or on your brush a few months into weight-loss treatment is unsettling, and it is one of the things people quietly search for at midnight. The honest short version: hair shedding is a recognised, listed side effect of both Mounjaro and Wegovy, early research suggests it is often a temporary shedding pattern that may be linked to the weight loss itself, and usually self-limiting. Current evidence does not point to permanent follicle damage, but it is worth mentioning to your prescribing clinician.

Quick answer (checked 30 September 2026): "Hair loss" appears as a common side effect (between 1 in 100 and 1 in 10 people) in the EU product information for both Mounjaro (tirzepatide) and Wegovy (semaglutide), mainly in people treated for weight management.

The pattern usually described is telogen effluvium, a diffuse shedding that tends to begin roughly 2 to 3 months after weight loss starts or speeds up, and that a 2026 systematic review (Gupta et al.) describes, in early and largely observational research, as typically reversible, with improvement generally seen within 3 to 6 months of weight stabilising. Nothing here is a promise about your own hair, and a doctor should look at any hair loss that is patchy, sudden or painful.

Check your eligibility — free 2-minute assessment

What the Irish product information actually says

In Ireland, the injections licensed for weight management are Mounjaro (tirzepatide) and Wegovy (semaglutide). (Ozempic, which people often name in this context, is licensed here for type 2 diabetes rather than weight management.) Both are authorised through the European Medicines Agency, so the EU Summary of Product Characteristics is the document to check, and we did:

Mounjaro: the EU product information lists hair loss in its table of adverse reactions in the "common" category (1 in 100 to fewer than 1 in 10 people), with a footnote that this reaction mainly applies to patients with overweight or obesity. The patient leaflet says hair loss was reported in patients treated for weight management.
Wegovy: "hair loss" is also listed as a common adverse reaction. The document states it was reported in 2.5% of patients treated with semaglutide versus 1.0% on placebo, that events were mainly mild, that most people recovered while continuing treatment, and that hair loss was reported more often in people with greater weight loss (20% or more).

Two things stand out. First, this is a known and documented effect, not a rare surprise. Second, the regulator's own wording links it to how much weight is lost, which fits with, but does not prove, the weight-loss explanation described below. Our broader side-effect guides cover the more common early effects: see Mounjaro side effects in Ireland and semaglutide side effects.

Why weight loss can make hair shed: telogen effluvium in plain English

Hair grows in cycles. At any moment most scalp hairs are in a long growing phase, and a smaller share are in a short resting phase (the "telogen" phase) before they fall out and are replaced. A significant physiological stress can push more hairs into the resting phase at once. A few months later, those hairs shed together. That delayed, diffuse shedding is called telogen effluvium.

Telogen effluvium is a recognised pattern after major physiological stress, and rapid weight loss is one of the triggers discussed in the literature. A 2021 review of hair loss after weight-loss surgery describes it as a non-scarring hair loss that shows up around three months after the triggering event.

What is new is that researchers are now asking the same question about injections. A 2026 systematic review of 24 studies (Gupta et al., Science Progress) found semaglutide and tirzepatide had the highest reported incidence of hair loss in the reviewed studies, with androgenetic hair loss (pattern thinning) and telogen effluvium the main subtypes reported, and tirzepatide most often linked to telogen effluvium.

Weight loss and reduced calorie or protein intake are the explanations the authors discuss; the mechanism is still being studied.

A balanced plate of salmon, eggs, spinach and lentils on a light kitchen counter

How common is it, and who notices it most?

Because different studies count differently, it helps to keep the figures in their own boxes rather than blend them:

Trial-level figure (Wegovy): 2.5% with semaglutide versus 1.0% with placebo, per the EU product information above.
Real-world records: a 2026 systematic review and meta-analysis of 17 studies, mostly cohort and pharmacovigilance data (about 1.09 million patient-exposures) reported that GLP-1 medicines were associated with roughly a 40% higher odds of non-scarring hair loss overall (pooled odds ratio 1.40), including telogen effluvium (adjusted odds ratio 1.76 at 12 months). Note that this is an association in mostly observational data, not proof of cause, and a higher relative risk of a small number is still a small number.
Who: the Gupta review reports women appear to be disproportionately affected, and the Wegovy product information notes hair loss was more frequent with greater weight loss.

Also worth knowing: a separate 2026 TriNetX cohort study found that people with hair-loss diagnoses on GLP-1 treatment had a lower follow-up BMI than those without, which may be consistent with a link to the size of weight loss, though it cannot show cause. That, again, is early observational research.

The timeline: when it starts, when it settles

The pattern described in the research is fairly consistent, though individual experience varies:

Trigger: weight loss begins, or speeds up after a dose increase.
Shedding starts about 2 to 3 months later. The Gupta review says shedding is expected around this delay after starting treatment or increasing dose if it is weight-loss related. That is why it can feel disconnected from the injection itself.
Settling: the same review describes telogen effluvium as typically reversible, with improvements generally observed within 3 to 6 months following weight stabilisation. Regrowth is typically gradual.

Those are typical patterns from the literature, not a schedule. Some people notice nothing at all, and others are affected for longer.

If shedding persists well beyond the timescales above, or you spot bald patches, scalp pain, or thinning that looks like a widening parting or receding temples rather than all-over shedding, that deserves a proper review, because other causes (thyroid conditions, iron deficiency, inherited pattern hair loss) can look similar. Telogen effluvium is also not the only kind of hair loss that GLP-1 studies report; androgenetic alopecia appears in the same data, and it is managed differently.

See if a supervised plan suits you — free check

A doctor's desk with a notepad, stethoscope and a cup of tea in soft daylight

What the research suggests, and what to ask your doctor

None of this is medical advice for your own case; it is what the reviews describe as sensible groundwork, and where the decisions belong with a clinician.

Pace. Preventive strategies in the Gupta review start with avoiding dramatic weight loss and severe calorie restriction. This is one reason supervised plans use scheduled dose reviews rather than pushing the fastest possible loss.
Enough protein and overall nutrition. The same review lists adequate protein, iron, zinc, vitamin D, B12 and vitamin A as part of preventing shedding, and notes GLP-1 use is associated with lower intake of protein and some micronutrients, largely because appetite drops. Some clinicians favour a food-first approach; the review lists protein and micronutrients as part of prevention strategies. Our guide on how to protect muscle while losing weight covers practical protein targets, and the same habits support hair.
A check for other causes. Where shedding is heavy or persistent, the reviews say blood tests (such as a full blood count, ferritin, thyroid function and vitamin D) may be considered to rule out other causes or spot deficiencies. That is a decision for your GP or prescribing clinician, not something to self-order.
Be careful with supplements. Nutritional optimisation has had moderate success in some telogen effluvium groups according to the Gupta review, but that is not the same as evidence that a particular supplement helps you. Taking high doses of some vitamins or minerals without a documented need may not help and can carry risks, so check first.
Do not stop treatment on your own. Decisions about pausing or changing a dose should be made with your prescriber. (The Wegovy product information notes most people recovered while continuing treatment, and the 2026 meta-analysis authors advise avoiding premature discontinuation.)
Pattern thinning is a different conversation. If your hair loss looks like inherited pattern thinning, the review mentions topical minoxidil for that pattern; whether it suits you is a decision for a GP or dermatologist.

One more reassurance from the Gupta review: there is no strong evidence of permanent follicle damage associated with GLP-1 use, and telogen effluvium is described as typically reversible. That is a statement about the evidence so far, not a guarantee.

A woman outdoors on an Irish coastal walk, wind in her hair, relaxed smile

Hear from real Slimbr members

Real Slimbr members, in their own words.

How a supervised plan keeps an eye on this from day one

Online assessment

A structured set of medical questions completed from home, reviewed by a clinician before anything is prescribed. Your history, including any existing thyroid, iron or hair concerns, is part of that picture.

Clinician-led pacing

Dose reviews happen on a schedule rather than on demand, so the speed of weight loss is something a doctor is watching, not something left to chance.

Nutrition guidance

Protein and food-first guidance is part of the plan, because eating enough of the right things when appetite is low supports overall nutrition.

Ongoing check-ins

If you notice hair shedding, you have a clinician to tell. They can help work out whether it fits the usual pattern or needs a closer look.

What hair shedding can look like on a well-paced plan

This is an illustrative timeline of the typical pattern described in the research, not a promise about your own hair or result.

Months 0–2Treatment begins at the lowest dose under clinician review. Appetite changes are commonly reported early on.

Months 2–4Some people notice increased shedding, the delayed effect of earlier weight change. Worth mentioning at a check-in.

Months 4–8Where shedding is telogen effluvium, in some people it may settle as weight stabilises; other causes get looked at if it does not.

AfterRegrowth is gradual, and the focus turns to maintaining your weight with good nutrition.

The take-home: hair shedding is a documented side effect that research suggests is usually temporary and may be related to the pace and size of weight loss, and it is one more reason to want a doctor rather than a shortcut in the loop.

Check your eligibility — it takes about 2 minutes

Frequently asked questions

Does Mounjaro cause hair loss?

Hair loss is listed as a common side effect in the EU product information for Mounjaro, mainly in people treated for weight management. Researchers are investigating whether it relates to the weight loss and reduced intake rather than the medicine itself; the mechanism is still being studied.

Does Wegovy cause hair loss?

It is also listed as common. The product information reports 2.5% of patients on semaglutide versus 1.0% on placebo, mostly mild, with most people recovering while continuing treatment.

Is the hair loss permanent?

The evidence so far suggests it is usually temporary. The 2026 review describes telogen effluvium as typically reversible, with improvement generally seen within 3 to 6 months of weight stabilising, and reports no strong evidence of permanent follicle damage. Individual experience varies, and inherited pattern thinning is a different condition.

When does it start?

Typically around 2 to 3 months after weight loss starts or speeds up, because of the delay in the hair cycle. That is why it can appear well after the first injections.

Should I take biotin or other supplements?

Speak to your GP or prescriber first. Reviews suggest correcting genuine deficiencies (for example iron) can matter, but a supplement is not a proven fix for everyone, and blood tests show whether you actually need one.

Should I stop treatment if my hair is shedding?

Do not stop on your own. Talk to your prescribing clinician, who can review your dose, pace and nutrition and check for other causes.

Weight loss with a doctor watching the details

If you have questions about treatment, the eligibility check is a low-pressure place to start. Answer the medical questions and a clinician reviews them against the licence criteria and tells you plainly whether a supervised plan could suit you. No pressure, no promises.

Begin your free eligibility check today

Hair Loss on Mounjaro and Wegovy in Ireland: What the Evidence Says